These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31098725)

  • 1. Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.
    Delamarre A; Tison F; Li Q; Galitzky M; Rascol O; Bezard E; Meissner WG
    J Neural Transm (Vienna); 2019 Jun; 126(6):789-793. PubMed ID: 31098725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Tison F; Nègre-Pagès L; Meissner WG; Dupouy S; Li Q; Thiolat ML; Thiollier T; Galitzky M; Ory-Magne F; Milhet A; Marquine L; Spampinato U; Rascol O; Bezard E
    Parkinsonism Relat Disord; 2013 Apr; 19(4):416-21. PubMed ID: 23283428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
    Mann RK; Edwards R; Zhou J; Jog M; Duval C
    Clin Neurol Neurosurg; 2010 Jun; 112(5):392-9. PubMed ID: 20206438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
    Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
    J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
    Giannakis A; Chondrogiorgi M; Tsironis C; Tatsioni A; Konitsiotis S
    J Neural Transm (Vienna); 2018 Sep; 125(9):1341-1349. PubMed ID: 29352351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
    Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A
    CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
    Havelund JF; Andersen AD; Binzer M; Blaabjerg M; Heegaard NHH; Stenager E; Faergeman NJ; Gramsbergen JB
    J Neurochem; 2017 Sep; 142(5):756-766. PubMed ID: 28628213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA; Williams DR
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
    J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.